Extended Data Fig. 6: Serum GDF-15 at baseline is not predictive for response, but positively associated with weight gain in phase 2a patients. | Nature

Extended Data Fig. 6: Serum GDF-15 at baseline is not predictive for response, but positively associated with weight gain in phase 2a patients.

From: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Extended Data Fig. 6: Serum GDF-15 at baseline is not predictive for response, but positively associated with weight gain in phase 2a patients.

(a) Serum GDF-15 levels at baseline of phase 2a NSCLC, UC and HCC patients according to RECIST 1.1 response assessment. (b) In NSCLC, UC and HCC patients with elevated GDF-15 (n = 17) serum levels at baseline weight gain is significantly higher than in patients with low GDF-15 (n = 21). Boxplots center line, median; box, IQR; whiskers, 1.5 x IQR; outliers are depicted individually. P values are reported from two-sided Mann-Whitney test.

Source Data

Back to article page